Form 4: Director Viola Mong Meehan Receives Cue Biopharma Options

Director Viola Mong Meehan was granted 1,626 stock options in Cue Biopharma, Inc. as part of standard equity compensation.

Summary

• Director Viola Mong Meehan received a grant of 1,626 stock options on May 30, 2026.
• The options have an exercise price of $21.90 per share.
• The options are scheduled to vest over a three-year period.
• One-third of the options vest on the first anniversary of the grant, with the remainder vesting in eight equal quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $21.90 exercise price.

Future Outlook

The options vest over a three-year period, indicating a long-term retention and incentive structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard equity compensation practices for non-employee directors in the biopharmaceutical industry.
• The use of stock options as a component of director compensation is a common practice among mid-cap and small-cap biotech firms to preserve cash.

Stakeholder Impact

• Shareholders: Minor potential for future dilution.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of one-third of the options on May 30, 2027.
• Quarterly vesting of the remaining balance thereafter.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Insider Trading, Stock Options, Director Compensation